Dose: 0.476 to 0.714 mg/kg
Single Dose: 0.59 (0.595)
Frequency: 8 hourly
Route: PO
Instructions: -

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

. It is of Synthetic origin and belongs to Aromatic Amino Acid. It belongs to L-amino acid decarboxylase inhibitor pharmacological group on the basis of mechanism of action and also classified in Antiparkinson Agents pharmacological group.The Molecular Weight of Benserazide (HCl) is 293.70.

Benserazide (HCl) is contraindicated in conditions like Psychosis,Narrow-angle glaucoma.

The severe or irreversible adverse effects of Benserazide (HCl), which give rise to further complications include Postural hypotension, Psychiatric disturbances, Fluctuating disability, Dyskinesias.Benserazide (HCl) produces potentially life-threatening effects which include Severe postural hypotension. which are responsible for the discontinuation of Benserazide (HCl) therapy.The signs and symptoms that are produced after the acute overdosage of Benserazide (HCl) include Hypotension, Nausea, Vomiting, Cardiac arrhythmias, Chorea.The symptomatic adverse reactions produced by Benserazide (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Elevated alkaline phosphatase, Elevated hepatic transaminases.

Benserazide (HCl) is primarily indicated in conditions like Parkinsonism.

No data regarding the interactions of Benserazide (HCl) was found.

Serum tests for bilirubin, catecholamines, creatinine, glucose and uric acid Urine tests for amino acids, creatinine, creatinine clearance, estrogens & glucose Urine tests for homogentisic acid, uric acid, ketones, vanillylmandelic acid & 5-OH ind acetic acid

Drug should not be given to Geriatrics, Neonates, and Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Powder Store in a well closed container. Protect from Sunlight and Moisture.

Rapidly affects oxygenation and lung compliance and should be restricted to a highly supervised use in a clinical setting with immediate availability of clinicians experienced with intubation and ventilatory management of the premature infants. If transient episode of the bradycardia and decreased oxygen saturation occur, discontinue the dosing procedure and initiate measures to alleviate the condition, produces rapid improvements in lungs oxygenation and compliance that may require immediate reductions in ventilator settings and FiO2.